INTERCEPT PHARMACEUTICALS, INC.

Lobbying client · New Jersey · filed 2025 to 2026

Pharmaceutical manufacturer

$0 Reported spend

7 Filings counted

1 Outside firm hired

0 Bills named

Spend is reported income plus in-house expenses across 7 filings. Everything on this page comes from one LDA client record (61397), filed by the registrant listed below.

Who filed for this client 1

SIDLEY AUSTIN LLP $0 Outside firm · 7 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

Reported by year 2 years

2026 $0 3 filings
2025 $0 4 filings

Recent filings 7 total

Q3 terminationNo activity

SIDLEY AUSTIN LLP

3rd Quarter 2026 (July 1 - Sep 30) · posted Oct 19, 2026

View → Q2 reportNo activity

SIDLEY AUSTIN LLP

2nd Quarter 2026 (Apr 1 - June 30) · posted Jul 20, 2026

View → Q1 reportNo activity

SIDLEY AUSTIN LLP

1st Quarter 2026 (Jan 1 - Mar 31) · posted Apr 20, 2026

View → Q4 reportNo activity

SIDLEY AUSTIN LLP

4th Quarter 2025 (Oct 1 - Dec 31) · posted Jan 20, 2026

View → Q3 reportNo activity

SIDLEY AUSTIN LLP

3rd Quarter 2025 (July 1 - Sep 30) · posted Oct 17, 2025

View → Q2 reportNo activity

SIDLEY AUSTIN LLP

2nd Quarter 2025 (Apr 1 - June 30) · posted Jul 18, 2025

View → Q1 reportNo activity

SIDLEY AUSTIN LLP

1st Quarter 2025 (Jan 1 - Mar 31) · posted Apr 18, 2025

View →

Keep going

Filings through October 19, 2026, the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.